Commercial-stage immunotherapy company ImmunityBio Inc (NASDAQ:IBRX) on Friday announced updated Phase 2 results from QUILT-3.078, evaluating a chemotherapy-free combination of ANKTIVA (nogapendekin alfa inbakicept) plus CAR-NK cell therapy in patients with recurrent glioblastoma (GBM).

The study has enrolled 23 patients, with 19 alive as of 22 January 2026. Median overall survival has not yet been reached.

Among 14 patients with evaluable data, the longest survival from disease recurrence has reached 12 months and is ongoing. Baseline mean absolute lymphocyte count (ALC) was 0.9 x 10³/µL, indicating severe lymphopenia, which increased to ≥1.4 x 10³/µL within one treatment cycle (p